Skip to content
GLP-1 Savers
Menu

Head-to-head · Value Score

Vitara RX vs NativeMed

Two GLP-1 deals, scored on the same six factors. Vitara RX lands a Value Score of 91, NativeMed a 72. Here's who gives you the honest lower price — and where each one bites back.

★ Better value

Vitara RX

#4 · Grade A · Best Value

Est. first month

$99/mo

Save ~93% vs brand-name
Get this deal Full Vitara RX review →
VS

NativeMed

#199 · Grade C · Watch List

Est. first month

From $149/mo (compounded)

Save ~89% vs brand-name
Get this deal Full NativeMed review →

The verdict

Better value: Vitara RX

Vitara RX takes it on Value Score, 91 to 72 an est. $99/mo first month, with no teaser step-up baked in. NativeMed isn't out of it: Shoppers who want sub-$200 promotional compounded GLP-1 pricing.

Our #1 overall:Neither of these is our top pick — that's CoreAge Rx (Value Score 93).See why →

Deal-by-deal

The numbers that decide it. Green ✓ marks the stronger side on each line.

DealVitara RXNativeMed
Value Score91 (A)72 (C)
Est. first month$99/moFrom $149/mo (compounded)
Save vs brand-name~93%~89%
Semaglutide$99/moFrom $149/mo (compounded)
Tirzepatide$149/moFrom $183/mo (compounded)
Both moleculesYesYes
PricingFlat — no step-upWatch
Coverage49 statesCoverage not published

Factor by factor

The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.

96
Lowest Real Price
82
Vitara RX: 96. NativeMed: 82.
90
No Teaser-Rate Bait
64
Vitara RX: 90. NativeMed: 64.
88
Nationwide Availability
45
Vitara RX: 88. NativeMed: 45.
92
Both Molecules
92
Vitara RX: 92. NativeMed: 92.
95
Easy Cancellation
58
Vitara RX: 95. NativeMed: 58.
67
Reputation
73
Vitara RX: 67. NativeMed: 73.

Vitara RX

VitaraRx is a direct-to-consumer telehealth marketplace offering compounded semaglutide and tirzepatide at flat per-drug pricing across all doses — no membership or hidden fees.

Why it's a deal

  • Among the lowest flat pricing in the market — $99/mo semaglutide and $149/mo tirzepatide, all doses same price
  • Names its 503A pharmacy partner (Manifest Pharmacy, Greer SC) — strong supply-chain transparency
  • LegitScript Certified
  • Publishes the FDA compounded-medication disclaimer
  • Covers 49 states with an explicit state list, not vague "most states" language

The fine print

  • No corporate legal entity disclosed — only the trade name "VitaraRx"
  • No named medical director — all clinical decisions made by independent providers (marketplace model)
  • All sales final — no medication returns
  • Per-vial mg quantity isn't clearly disclosed, making price comparisons harder
  • Doesn't ship to Alaska

NativeMed

NativeMed, LLC (nativemed.net) is a Miami, FL-based cash-pay telehealth provider offering compounded semaglutide at promotional $149/mo (regular $299) and compounded tirzepatide at promotional $183/mo…

Why it's a deal

  • LegitScript Certified (verifiable in the footer)
  • Promotional pricing shown publicly: $149/mo semaglutide, $183/mo tirzepatide
  • Online questionnaire intake, with a live visit added when state law requires it

The fine print

  • Pharmacy partners aren't named — described only as 'USA-based' or 'accredited' pharmacies
  • States served aren't listed publicly
  • Prices are promotional — confirm whether they hold past month one or rise to the $299/$399 regular rate
Get the Vitara RX deal Get the NativeMed deal

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.

Neither one the right fit? Every program that outscores Vitara RX is ranked on the Vitara RX alternatives board, and the same list for the other side is on alternatives to NativeMed.

More head-to-heads

← All comparisons

Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.